MAP - Market Access Podcast

By Dr. Stefan WalzerBusiness Science Medicine Health & Fitness

MAP - Market Access Podcast episodes

December 15, 2022 Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?
In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might be questioned by some. However, if the pathway is clear and the company knows how to approach payers and asks the right questions it provides valuable insights securing commercial success. Within the podcast the European, UK and German pathways are being discussed including how to approach payers and what to ask them. Get the right insights from a great discussion between these market access experts!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #UK #Germany
39 min
December 01, 2022 The AMNOG process - how does it work from a legal perspective, Alexander Meier?
New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stefan Walzer and the experienced market access lawyer Alexander Meier.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #AMNOG #law #lawyer
40 min
November 15, 2022 What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?
In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and pricing including buckets being discussed within this episode:
1) ATMPs
2) EU joint HTA
3) Digital Health
4) Germany / AMNOG
5) European reimbursement

Please enjoy this compressed summary and let us know your questions that we should cover in the following podcast episodes.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #europe #ispor #isporeurope
53 min
November 01, 2022 AMNOG Reform - will Germany remain the most attractive market for orphan drugs?
Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices.
This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discussion Dr. Stefan Walzer discusses with Owen Bryant, Georgie Rack and Fisentzos Stylianou, all working at Partners 4 Access, the specifics of orphan drugs in the AMNOG context. (https://partners4access.com/insights/podcasts/)
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany
42 min
October 15, 2022 Why should Market Access Managers care about statistics, Alexander Schacht?
Not everybody can be a statistician, but >The Effective Statistician< Alexander Schacht argues, that every Market Access Manager should work with statisticians and should learn how to communicate statistics effectively. Together with Dr. Stefan Walzer he is framing the needs and importance of statistics in the context of market access and reimbursement.
Don’t miss this insightful conversation!
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #statistics
36 min
October 01, 2022 How might digitization change health care in Germany by 2035, Julian Molitor?
Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.
Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with respect to digitization you should not miss this podcast episode.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #digitalisation #germany
31 min
September 15, 2022 Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?
Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. Dr. But which health insurance companies should contacted and how? What makes a contarct attractive for a health insurance?
Stefan Walzer and Tim Hering, experienced in integrated care contracts, are discussing the unique possibilities with smart contracts.
Don’t miss this insightful conversation!
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany
29 min
September 01, 2022 Would AI substitute or (only) support market access managers, Dr. Andree Bates?
Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?
Further reading is available on "How to Embed AI into the Market Access Process“: https://eularis.com/resources

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence
32 min
August 15, 2022 How successful is the DiGA fast track, Dr. Henrik Matthies ?
Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think tank of the federal ministry of health in Germany. The first project of agile lawmaking in Germany. What are key takeaways and learnings from 2 years DiGAs? What are pitfalls with a focus on BfArM and the German payers (GKV-SV)? How to be successful in the German DiGA environment?
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #diga
34 min
August 01, 2022 The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how one could identify the optimal path for their product (including digital health)…
Dr. Stefan Walzer and his guests Dr. Paul Craddy and Dr. Graham Foxon from Remap Consulting are discussing these and many other questions around market access in the UK.
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #uk #england #scotland #wales #nice
34 min

About MAP - Market Access Podcast

From the publisher's feed

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.

The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.

Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).

Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.

Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.